A. Rachel Leheny

A. Rachel Leheny has filed trades across 2 companies (mainly through SEC (Form 4)), most often in CalciMedica, Inc. and Anthera Pharmaceuticals Inc. Over a trading history stretching from 4 March 2010 to 25 June 2026, the count stands at 31 filings.

Every open-market trade on record is a purchase: 18 purchases worth €714k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The rest of the record consists of 8 share grants and 1 option exercise.

In size, the median ticket on the buying side is €4,820. Of 17 purchases, 17 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. After 12 purchases with a full 90-day history, the hit rate stands at 33% and the median 90-day move at -16.4%. Past outcomes like these are no guarantee of what comes next.

The latest filing, published on 29 June 2026, reports a share grant in CalciMedica, Inc. The clock since the last published purchase (21 July 2025) now reads 460 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.